http://ideas.eyeconx.net/story.php?title=lucentis-ranibizumab-for-treating-visual-impairment-due-to-diabetic-macular-oedema-study-shows-new-evidence New data for Lucentis® (ranibizumab) has demonstrated improvement in visual acuity achieved with individualized treatment after one year is maintained for up to three years on average in patients with VI-DMO, with fewer injections in years two and three compared to the first year and no additional or new safety risks identified1.The findings come from the RESTORE extension study which showed that ... Tue, 11 Sep 2012 12:37:06 EDT en